## Despoina Koulenti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9271125/publications.pdf

Version: 2024-02-01

109321 7,180 91 35 citations h-index papers

g-index 99 99 99 7788 docs citations times ranked citing authors all docs

56724

83

#	Article	IF	CITATIONS
1	Current Perspectives on the Diagnosis and Management of Healthcare-Associated Ventriculitis and Meningitis. Infection and Drug Resistance, 2022, Volume 15, 697-721.	2.7	29
2	Epidemiology and age-related mortality in critically ill patients with intra-abdominal infection or sepsis: an international cohort study. International Journal of Antimicrobial Agents, 2022, 60, 106591.	2.5	14
3	Epidemiology of Candidemia and Fluconazole Resistance in an ICU before and during the COVID-19 Pandemic Era. Antibiotics, 2022, 11, 771.	3.7	23
4	Clinical Features and Outcomes of Monobacterial and Polybacterial Episodes of Ventilator-Associated Pneumonia Due to Multidrug-Resistant Acinetobacter baumannii. Antibiotics, 2022, 11, 892.	3.7	7
5	Protocol for an international, multicentre, prospective, observational study of nosocomial pneumonia in intensive care units: the PneumolNSPIRE study. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2021, 23, 59-66.	0.1	O
6	Nosocomial Pneumonia in the Era of Multidrug-Resistance: Updates in Diagnosis and Management. Microorganisms, 2021, 9, 534.	3.6	15
7	An international survey on aminoglycoside practices in critically ill patients: the AMINO III study. Annals of Intensive Care, 2021, $11$ , 49.	4.6	15
8	How to measure microaspiration of subglottic secretions in clinical research in intubated patients?. Intensive and Critical Care Nursing, 2021, 63, 103010.	2.9	4
9	Antimicrobial stewardship in the ICU in COVID-19 times: the known unknowns. International Journal of Antimicrobial Agents, 2021, 58, 106409.	2.5	24
10	Patterns in the epidemiology of candidemia as a consequence of antibiotic and antifungal exposure. Burns, 2020, 46, 500-501.	1.9	1
11	Evaluation of the quality of evidence supporting guideline recommendations for the nutritional management of critically ill adults. Clinical Nutrition ESPEN, 2020, 39, 144-149.	1.2	4
12	Quality of evidence supporting Surviving Sepsis Campaign Recommendations. Anaesthesia, Critical Care & Care	1.4	5
13	Editorial for Special Issue "Multidrug-Resistant Pathogens― Microorganisms, 2020, 8, 1383.	3.6	5
14	Nosocomial pneumonia diagnosis revisited. Current Opinion in Critical Care, 2020, 26, 442-449.	3.2	6
15	Pathogenesis-Targeted Preventive Strategies for Multidrug Resistant Ventilator-Associated Pneumonia: A Narrative Review. Microorganisms, 2020, 8, 821.	3.6	10
16	Pandrug-resistant Acinetobacter baumannii treatment: still a debatable topic with no definite solutions. Journal of Antimicrobial Chemotherapy, 2020, 75, 3081-3081.	3.0	9
17	Colistin-Resistant Acinetobacter Baumannii Bacteremia: A Serious Threat for Critically Ill Patients. Microorganisms, 2020, 8, 287.	3.6	41
18	Emerging Treatment Options for Infections by Multidrug-Resistant Gram-Positive Microorganisms. Microorganisms, 2020, 8, 191.	3.6	29

#	Article	IF	Citations
19	Ventilator-Associated Tracheobronchitis: To Treat or Not to Treat?. Antibiotics, 2020, 9, 51.	3.7	13
20	Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms. Microorganisms, 2019, 7, 270.	3.6	63
21	Epidemiology of intra-abdominal infection and sepsis in critically ill patients: "AbSeSâ€; a multinational observational cohort study and ESICM Trials Group Project. Intensive Care Medicine, 2019, 45, 1703-1717.	8.2	103
22	Lefamulin. Comment on: "Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms. Microorganisms, 2019, 7, 270― Microorganisms, 2019, 7, 386.	3.6	14
23	Intravenous fosfomycin for the treatment of multidrug-resistant pathogens: what is the evidence on dosing regimens?. Expert Review of Anti-Infective Therapy, 2019, 17, 201-210.	4.4	17
24	The relationship between ventilator-associated pneumonia and chronic obstructive pulmonary disease: what is the current evidence?. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 637-647.	2.9	12
25	Factors associated with ventilator-associated events: an international multicenter prospective cohort study. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 1693-1699.	2.9	18
26	The Role of Minocycline in the Treatment of Nosocomial Infections Caused by Multidrug, Extensively Drug and Pandrug Resistant Acinetobacter baumannii: A Systematic Review of Clinical Evidence. Microorganisms, 2019, 7, 159.	3.6	42
27	Diagnosing invasive pulmonary aspergillosis in ICU patients: putting the puzzle together. Current Opinion in Critical Care, 2019, 25, 430-437.	3.2	33
28	Pharmacokinetic evaluation of linezolid administered intravenously in obese patients with pneumonia. Journal of Antimicrobial Chemotherapy, 2019, 74, 667-674.	3.0	22
29	Prospective observational cohort study on grading the severity of postoperative complications in global surgery research. British Journal of Surgery, 2019, 106, e73-e80.	0.3	13
30	Infections by multidrug-resistant Gram-negative Bacteria: What's new in our arsenal and what's in the pipeline?. International Journal of Antimicrobial Agents, 2019, 53, 211-224.	2.5	68
31	The CVC and CRBSI: don't use it and lose it!. Intensive Care Medicine, 2018, 44, 238-240.	8.2	3
32	The surgical safety checklist and patient outcomes after surgery: a prospective observational cohort study, systematic review and meta-analysis. British Journal of Anaesthesia, 2018, 120, 146-155.	3.4	92
33	Nebulization of antimicrobial agents in mechanically ventilated adults in 2017: an international cross-sectional survey. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 785-794.	2.9	25
34	Candida burn wound sepsis: The "holy trinity―of management. Intensive and Critical Care Nursing, 2018, 46, 4-5.	2.9	4
35	Microbial cause of ICU-acquired pneumonia: hospital-acquired pneumonia versus ventilator-associated pneumonia. Current Opinion in Critical Care, 2018, 24, 332-338.	3.2	78
36	Assessing predictive accuracy for outcomes of ventilator-associated events in an international cohort: the EUVAE study. Intensive Care Medicine, 2018, 44, 1212-1220.	8.2	41

#	Article	IF	CITATIONS
37	Nosocomial pneumonia in 27 ICUs in Europe: perspectives from the EU-VAP/CAP study. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 1999-2006.	2.9	230
38	Optimizing educational initiatives to prevent ventilator-associated complications. American Journal of Infection Control, 2017, 45, 102-103.	2.3	2
39	What We Learned From the EU-VAP/CAP Study for Severe Pneumonia. Clinical Pulmonary Medicine, 2017, 24, 112-120.	0.3	0
40	Critical care admission following elective surgery was not associated with survival benefit: prospective analysis of data from 27 countries. Intensive Care Medicine, 2017, 43, 971-979.	8.2	108
41	The authors reply. Critical Care Medicine, 2017, 45, e735-e736.	0.9	0
42	Cumulative Evidence of Randomized Controlled and Observational Studies on Catheter-Related Infection Risk of Central Venous Catheter Insertion Site in ICU Patients: A Pairwise and Network Meta-Analysis. Critical Care Medicine, 2017, 45, e437-e448.	0.9	59
43	Improved survival among ICU-hospitalized patients with community-acquired pneumonia by unidentified organisms: a multicenter case–control study. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 123-130.	2.9	10
44	Evaluating rates of ventilator-associated pneumonia: Consider patient, organizational & educational risk factors. Indian Journal of Medical Research, 2017, 145, 697-698.	1.0	2
45	The value of polyurethane-cuffed endotracheal tubes to reduce microaspiration and intubation-related pneumonia: a systematic review of laboratory and clinical studies. Critical Care, 2016, 20, 203.	5.8	35
46	Global patient outcomes after elective surgery: prospective cohort study in 27 low-, middle- and high-income countries. British Journal of Anaesthesia, 2016, 117, 601-609.	3.4	400
47	Characteristics and risk factors for 28-day mortality of hospital acquired fungemias in ICUs: data from the EUROBACT study. Critical Care, 2016, 20, 53.	5.8	59
48	Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort. Journal of Antimicrobial Chemotherapy, 2016, 71, 196-207.	3.0	129
49	Factors Influencing Outcomes in Intensive Care Unit Patients with Nosocomial Infections. Archives of Iranian Medicine, 2016, 19, 677-8.	0.6	0
50	Angiopoietin-2 associations with the underlying infection and sepsis severity. Cytokine, 2015, 73, 163-168.	3.2	29
51	World alliance against antibiotic resistance: The WAAAR declaration against antibiotic resistance. Medicina Intensiva, 2015, 39, 34-39.	0.7	14
52	Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study. Critical Care, 2015, 19, 33.	5.8	108
53	The Surviving Sepsis Campaign bundles and outcome: results from the International Multicentre Prevalence Study on Sepsis (the IMPreSS study). Intensive Care Medicine, 2015, 41, 1620-1628.	8.2	323
54	Point prevalence of surgical checklist use in Europe: relationship with hospital mortality. British Journal of Anaesthesia, 2015, 114, 801-807.	3.4	35

#	Article	IF	CITATIONS
55	COPD patients with ventilator-associated pneumonia: implications for management. European Journal of Clinical Microbiology and Infectious Diseases, 2015, 34, 2403-2411.	2.9	29
56	Population Pharmacokinetics of Fosfomycin in Critically III Patients. Antimicrobial Agents and Chemotherapy, 2015, 59, 6471-6476.	3.2	59
57	Infections, antibiotic treatment and mortality in patients admitted to ICUs in countries considered to have high levels of antibiotic resistance compared to those with low levels. BMC Infectious Diseases, 2014, 14, 513.	2.9	20
58	Approach to invasive pulmonary aspergillosis in critically ill patients. Current Opinion in Infectious Diseases, 2014, 27, 174-183.	3.1	61
59	Prevalence, Risk Factors, and Mortality for Ventilator-Associated Pneumonia in Middle-Aged, Old, and Very Old Critically Ill Patients*. Critical Care Medicine, 2014, 42, 601-609.	0.9	150
60	Update in Hospital-acquired Bacteremia Respiratory Infections. Clinical Pulmonary Medicine, 2014, 21, 9-15.	0.3	3
61	Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: Lessons from the DALI Study. International Journal of Antimicrobial Agents, 2014, 43, 423-430.	2.5	48
62	What's new in invasive pulmonary aspergillosis in the critically ill. Intensive Care Medicine, 2014, 40, 723-726.	8.2	22
63	DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current Â-Lactam Antibiotic Doses Sufficient for Critically III Patients?. Clinical Infectious Diseases, 2014, 58, 1072-1083.	5.8	843
64	Reply to Rhodes et al. Clinical Infectious Diseases, 2014, 59, 907-908.	5.8	2
65	Respiratory infections in patients undergoing mechanical ventilation. Lancet Respiratory Medicine, the, 2014, 2, 764-774.	10.7	59
66	Risk factors for target non-attainment during empirical treatment with $\hat{l}^2$ -lactam antibiotics in critically ill patients. Intensive Care Medicine, 2014, 40, 1340-1351.	8.2	147
67	Persistence of colonisation with MDRO following discharge from the ICU. Intensive Care Medicine, 2014, 40, 603-605.	8.2	6
68	Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study. Critical Care, 2014, 18, R99.	5.8	87
69	Hospital mortality of adults admitted to Intensive Care Units in hospitals with and without Intermediate Care Units: a multicentre European cohort study. Critical Care, 2014, 18, 551.	5.8	154
70	The authors reply. Critical Care Medicine, 2014, 42, e314-e315.	0.9	1
71	Potentially resistant microorganisms in intubated patients with hospital-acquired pneumonia: the interaction of ecology, shock and risk factors. Intensive Care Medicine, 2013, 39, 672-681.	8.2	114
72	What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review. International Journal of Antimicrobial Agents, 2013, 42, 289-293.	2.5	63

#	Article	IF	Citations
73	Diagnosis and management of temperature abnormality in ICUs: a EUROBACT investigators' survey. Critical Care, 2013, 17, R289.	5.8	32
74	Critically Ill Elderly Adults with Infection: Analysis of the Extended Prevalence of Infection in Intensive Care Study. Journal of the American Geriatrics Society, 2013, 61, 2065-2071.	2.6	34
75	Mortality after surgery in Europe: a 7 day cohort study. Lancet, The, 2012, 380, 1059-1065.	13.7	1,614
76	Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study. Intensive Care Medicine, 2012, 38, 1930-1945.	8.2	322
77	DALI: Defining Antibiotic Levels in Intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic. BMC Infectious Diseases, 2012, 12, 152.	2.9	47
78	107. Critical Care Medicine, 2012, 40, 1-328.	0.9	0
79	491. Critical Care Medicine, 2012, 40, 1-328.	0.9	0
80	Bacteremia is an independent risk factor for mortality in nosocomial pneumonia: a prospective and observational multicenter study. Critical Care, 2011, 15, R62.	5.8	87
81	Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenzaÂA infection. Intensive Care Medicine, 2011, 37, 272-283.	8.2	188
82	Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia. European Respiratory Journal, 2011, 37, 1332-1339.	6.7	78
83	Patient to Nurse Ratio and Risk of Ventilator-Associated Pneumonia in Critically Ill Patients. American Journal of Critical Care, 2011, 20, e1-e9.	1.6	43
84	Spectrum of practice in the diagnosis of nosocomial pneumonia in patients requiring mechanical ventilation in European intensive care units. Critical Care Medicine, 2009, 37, 2360-2369.	0.9	188
85	Quality of Life Outcome of Critical Care Survivors Eighteen Months after Discharge from Intensive Care. Croatian Medical Journal, 2007, 48, 814-821.	0.7	27
86	Oral care practices in intensive care units: aÂsurvey of 59 European ICUs. Intensive Care Medicine, 2007, 33, 1066-1070.	8.2	134
87	Sepsis in Obstetrics. , 2007, , 488-493.		0
88	Hospital-acquired pneumonia in the 21st century: a review of existing treatment options and their impact on patient care. Expert Opinion on Pharmacotherapy, 2006, 7, 1555-1569.	1.8	26
89	Gram-negative bacterial pneumonia: aetiology and management. Current Opinion in Internal Medicine, 2006, 5, 358-364.	1.5	15
90	Desmoid Tumor Presenting as Intra-Abdominal Abscess. Digestive Diseases and Sciences, 2006, 51, 68-69.	2.3	22

# ARTICLE IF CITATIONS
91 Hospital-Acquired Pneumonia Caused by Staphylococcus aureus., 0,, 107-129. o